drugset / Trial / NCT01383486

Self Selection Trial of Naproxen Sodium

NCT01383486

Phase 3 Completed 253 enrolled Bayer
Non-randomizedParallel-groupOpen-label

Summary

A pilot trial to demonstrate that consumers can appropriately select Aleve 24 Hour for their own use based on expected duration of pain greater than 12 hours.

Timeline

Start
2011-07
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibuprofen Small molecule 200 mg Oral
Subject Naproxen Small molecule 660 mg Oral

Indications

No indication recorded.